| Acute lymphocytic leukemia

Besponsa vs Oncaspar

Side-by-side clinical, coverage, and cost comparison for acute lymphocytic leukemia.

Deep comparison between: Besponsa vs Oncaspar with Prescriber.AI

AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.

Safety signalsOncaspar has a higher rate of injection site reactions vs Besponsa based on FDA-approved prescribing information

Coverage gaps3 major payers require step therapy for Oncaspar but not Besponsa, including UnitedHealthcare

Category

Besponsa

Oncaspar

At A Glance

RouteIV infusion

FrequencyDays 1, 8, and 15 per cycle

ClassCD22-directed antibody-drug conjugate

RouteIM injection or IV infusion

FrequencyEvery 14 days

ClassPEGylated L-asparaginase

Indications

Acute lymphocytic leukemia

Acute lymphocytic leukemia

Dosing

Acute lymphocytic leukemia Cycle 1: 1.8 mg/m2/cycle as 0.8 mg/m2 on Day 1 and 0.5 mg/m2 on Days 8 and 15 (21-day cycle, extendable to 28 days); subsequent cycles (CR/CRi): 1.5 mg/m2/cycle as 0.5 mg/m2 on Days 1, 8, and 15 (28-day cycle); subsequent cycles (non-CR/CRi): 1.8 mg/m2/cycle as 0.8 mg/m2 on Day 1 and 0.5 mg/m2 on Days 8 and 15 (28-day cycle); administered by IV infusion over 1 hour with premedication (corticosteroid, antipyretic, antihistamine).

Acute lymphocytic leukemia 2,500 IU/m2 (age <=21 years) or 2,000 IU/m2 (age >21 years) IM or IV, no more frequently than every 14 days.

Contraindications

—

History of serious hypersensitivity reactions, including anaphylaxis, to ONCASPAR or any excipient
History of serious thrombosis with prior L-asparaginase therapy
History of pancreatitis, including pancreatitis related to prior L-asparaginase therapy
History of serious hemorrhagic events with prior L-asparaginase therapy
Severe hepatic impairment

Drug Interactions

1075View drug interactions

1003View drug interactions

Adverse Reactions

Most common (>=20%) Thrombocytopenia, neutropenia, infection, anemia, leukopenia, fatigue, hemorrhage, pyrexia, nausea, headache, febrile neutropenia, transaminases increased, abdominal pain, gamma-glutamyltransferase increased, hyperbilirubinemia

Serious Infection, febrile neutropenia, hemorrhage, abdominal pain, pyrexia, veno-occlusive disease (VOD), fatigue

Most common (>5%) Elevated transaminase, febrile neutropenia, hypertriglyceridemia, hypoalbuminemia, bilirubin increased, hyperglycemia, pancreatitis, abnormal clotting studies, embolic and thrombotic events, hypersensitivity, sepsis, infections

Serious Anaphylaxis and serious hypersensitivity reactions, thrombosis, pancreatitis, glucose intolerance, hemorrhage, hepatotoxicity including veno-occlusive disease

Postmarketing Coagulopathy, hepatic impairment, pancreatic cyst, veno-occlusive disease, anaphylactic shock, blood cholesterol increased, hyperglycemia, hyperammonemia, osteonecrosis, hemorrhage including CNS hemorrhage, thrombosis including superior sagittal sinus thrombosis

Pharmacology

CD22-directed antibody-drug conjugate (ADC); inotuzumab binds CD22-expressing tumor cells, enabling internalization and intracellular release of N-acetyl-gamma-calicheamicin dimethylhydrazide, which induces double-strand DNA breaks leading to cell cycle arrest and apoptotic cell death.

ONCASPAR is a PEGylated L-asparaginase that catalyzes the conversion of L-asparagine to aspartic acid and ammonia, depleting plasma asparagine and killing leukemic cells that have low asparagine synthetase expression and depend on an exogenous asparagine source for survival.

View Full FDA Information

View full FDA information

Enter your patient's insuranceCheck specific coverage details for your patient.

Most Common Insurance

Anthem BCBS

Besponsa